المعالجة الكيماوية وفق البروتوكول VIP (Vepeside + Ifosfamide + Carpoplatine)‎ في مرضى لمفوما هودجكن المتقدم (الناكس و المعند (في مشفى المواساة الجامعي

Abstract EN

Background: Hodgkin's lymphoma (HL) is a disease of good response on initial radio-chemotherapy, but there is a ratio of 5-35% does not respond, and some relapses after initial chemotherapy (CT) appear to have a poor prognosis, especially if the duration of the first complete remission (CR) was short.

So the aim was to improve the survival by use the combination of VIP .

Methods And Patients: Prospective Study of patients with Hodgkin's lymphoma, of age more than 13 years, who had relapses after combination of ABVD, and the resistant cases.

Diagnosed in Almouassat hospital, within 1\2004- 1\2oo9.

Then the patients were treated with the combination of VIP.

Evaluation of relapse and resistant depended on CT-scan, biopsy, and Gallium scanning.

Results: 32 patients were in first relapse or resistance.

they were divided into 3 groups, group-1: included 15 patients (47%) without bad prognosis, the interval of end treatment- relapse is about 4,5 years, Treated with ABVD.

result was complete remission in 12 patients ( 80% ).

Group- 2; included nine relapsed patients with bad prognosis; the interval of end treatment- relapse is about 1 year, treated with combination of VIP and Radiation Therapy if It is necessary.

Result was complete remission in 3 patients, partial remission in 3 patients, and resistance in 2 patients.

The whole response is 78%.

Group- 3; included 6 resistant patients, treated with combination of VIP combination CT followed by radiotherapy (RT), result was complete remission in 4 patients (78%), partial remission in 2 patients.

There was a significant difference, especially in group-3.

Conclusion: The protocol ABVD is still the treatment of choice in patients with far relapse and without bad prognosis.

while The combination of VIP, followed by radiotherapy or no, is useful and efficacy in resistant and relapse Hodgkin's lymphoma.